Genentech rejects Roche bid

By Kate McDonald
Friday, 15 August, 2008

A special committee of US biotechnology giant Genentech’s board of directors has rejected a proposal by Swiss pharma Roche to buy out the company for US$43.7 billion.

Roche, which already owns 56 per cent of Genentech, was offering $89 per share for the remaining 44 per cent.

The Genentech directors said the offer undervalued the company but would consider a new proposal at a price it considered worthy.

Genentech’s stocks were trading on the New York Stock Exchange at close to $100 this week.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd